Section 5 - Infections after Hematopoietic Cell Transplantation: Progress?

Marr, KA. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology Am Soc Hematol Educ Program. 2012;2012:265–70.Google ScholarPubMed

Hiemenz, JW. Management of infections complicating allo-hematopoietic stem cell transplantation. Semin Hematol. 2009;46:289–312.CrossRefGoogle Scholar

Freifeld, AG, Bow, EJ, Sepkowitz, KA, Boeckh, MJ, Ito, JI, Mullen, CA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–93.CrossRefGoogle Scholar

Martinho, GH, Romanelli, RM, Teixeira, GM, Macedo, AV, Chaia, JM, Nobre, V. Infectious complications associated with the use of central venous catheters in patients undergoing hematopoietic stem cell transplantation. Am J Infect Control. 2013;41:642–4.CrossRefGoogle Scholar

Averbuch, D, Cordonnier, C, Livermore, DM, Mikulska, M, Orasch, C, Viscoli, C, et al.; ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98:1836–47.CrossRefGoogle Scholar

Viscoli, C, Bruzzi, P, Castagnola, E, Boni, L, Calandra, T, Gaya, H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer. 1994;30A:430–7Google Scholar

Viscoli, C; EORTC International Antimicrobial Therapy Group. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer. 2002;38(Suppl 4):S82–7.CrossRefGoogle Scholar

Zinner, SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–4.CrossRefGoogle ScholarPubMed

Wisplinghoff, H, Seifert, H, Wenzel, RP, Edmond, MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10.CrossRefGoogle ScholarPubMed

Oliveira, AL, de Souza, M, Carvalho-Dias, VM, Ruiz, MA, Silla, L, Tanaka, PY, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant Gramnegative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–81.CrossRefGoogle Scholar

Weinstock, DM, Conlon, M, Iovino, C, Aubrey, T, Gudiol, C, Riedel, E, et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allo-hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13:615–21.CrossRefGoogle Scholar

Gudiol, C, Tubau, F, Calatayud, L, Garcia-Vidal, C, Cisnal, M, Sánchez-Ortega, I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66:657–63.CrossRefGoogle ScholarPubMed

Arnan, M, Gudiol, C, Calatayud, L, Liñares, J, Dominguez, MÁ, Batlle, M, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:355–60.CrossRefGoogle ScholarPubMed

Gudiol, C, Calatayud, L, Garcia-Vidal, C, Lora-Tamayo, J, Cisnal, M, Duarte, R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–41.CrossRefGoogle ScholarPubMed

Trecarichi, EM, Tumbarello, M, Spanu, T, Caira, M, Fianchi, L, Chiusolo, P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299–307.CrossRefGoogle ScholarPubMed

Trecarichi, EM, Tumbarello, M, Caira, M, Candoni, A, Cattaneo, C, Pastore, D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011; 96:e1–3CrossRefGoogle ScholarPubMed

Satlin, MJ, Jenkins, SG, Walsh, TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;58:1274–83.CrossRefGoogle ScholarPubMed

Busca, A, Cavecchia, I, Locatelli, F, D’Ardia, S, De Rosa, FG, Marmont, F, et al. Blood stream infections after allo- stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012;14:40–8.CrossRefGoogle Scholar

Mikulska, M, Del Bono, V, Bruzzi, P, Raiola, AM, Gualandi, F, Van Lint, MT, et al. Mortality after bloodstream infections in allo-haematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40:271–8.CrossRefGoogle Scholar

Mendes, ET, Dulley, F, Basso, M, Batista, MV, Coracin, F, Guimarães, T, et al. Healthcare-associated infection in hematopoietic stem cell transplantation patients: risk factors and impact on outcome. Int J Infect Dis. 2012;16:e424–8.CrossRefGoogle ScholarPubMed

Hong, J, Moon, SM, Ahn, HK, Sym, SJ, Park, YS, Park, J, et al. Comparison of characteristics of bacterial bloodstream infection between adult patients with allo- and auto- hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:994–9.CrossRefGoogle ScholarPubMed

Srinivasan, A, Wang, C, Srivastava, DK, Burnette, K, Shenep, JL, Leung, W, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allo- hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:94–101.CrossRefGoogle Scholar

Kim, SH, Kee, SY, Lee, DG, Choi, SM, Park, SH, Kwon, JC, et al. Infectious complications following allo- stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens. Transpl Infect Dis. 2013;15:49–59.CrossRefGoogle ScholarPubMed

Sarashina, T, Yoshida, M, Iguchi, A, Okubo, H, Toriumi, N, Suzuki, D, et al. Risk factor analysis of bloodstream infection in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2013;35:76–80.CrossRefGoogle ScholarPubMed

Bock, AM, Cao, Q, Ferrieri, P, Young, JA, Weisdorf, DJ. Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant. 2013;19:102–8.CrossRefGoogle ScholarPubMed

Piñana, JL, Montesinos, P, Martino, R, Vazquez, L, Rovira, M, López, J, et al. Incidence, risk factors, and outcome of bacteremia following auto- hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93:299–307.CrossRefGoogle Scholar

Seo, SK, Xiao, K, Huang, YT, Jongwutiwes, U, Chung, D, Maloy, M, et al. Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allo- hematopoietic stem cell transplant (HSCT) recipients: A 12-year single institution study. J Infect. 2014 Jun 12. pii: S0163-4453(14)00163–7.

Gudiol, C, Bodro, M, Simonetti, A, Tubau, F, González-Barca, E, Cisnal, M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19:474–9.CrossRefGoogle ScholarPubMed

Munoz-Price, LS, Poirel, L, Bonomo, RA, Schwaber, MJ, Daikos, GL, Cormican, M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.CrossRefGoogle Scholar

Tzouvelekis, LS, Markogiannakis, A, Psichogiou, M, Tassios, PT, Daikos, GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682–707.CrossRefGoogle ScholarPubMed

Cantón, R, Akóva, M, Carmeli, Y, Giske, CG, Glupczynski, Y, Gniadkowski, M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18:413–31.CrossRefGoogle Scholar

Giani, T, D’Andrea, MM, Pecile, P, Borgianni, L, Nicoletti, P, Tonelli, F, et al. Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J Clin Microbiol. 2009;47:3793–4.CrossRefGoogle ScholarPubMed

Fontana, C, Favaro, M, Sarmati, L, Natoli, S, Altieri, A, Bossa, MC, et al. Emergence of KPC-producing Klebsiella pneumoniae in Italy. BMC Res Notes. 2010;3:40.CrossRefGoogle ScholarPubMed

Gaibani, P, Ambretti, S, Berlingeri, A, Gelsomino, F, Bielli, A, Landini, MP, et al. Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large Italian hospital: surveillance period 1 March - 30 September 2010. Euro Surveill. 2011;16(8).Google Scholar

Giani, T, Pini, B, Arena, F, Conte, V, Bracco, S, Migliavacca, R; AMCLI-CRE Survey Participants, Pantosti, A, Pagani, L, Luzzaro, F, Rossolini, GM. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013;18(22).Google ScholarPubMed

Tumbarello, M, Viale, P, Viscoli, C, Trecarichi, EM, Tumietto, F, Marchese, A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.CrossRefGoogle ScholarPubMed

Zarkotou, O, Pournaras, S, Tselioti, P, Dragoumanos, V, Pitiriga, V, Ranellou, K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–803.CrossRefGoogle Scholar

Clancy, CJ, Chen, L, Shields, RK, Zhao, Y, Cheng, S, Chavda, KD, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13:2619–33.CrossRefGoogle ScholarPubMed

Gupta, N, Limbago, BM, Patel, JB, Kallen, AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–7.CrossRefGoogle Scholar

Zuckerman, T, Benyamini, N, Sprecher, H, Fineman, R, Finkelstein, R, Rowe, JM, et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant. 2011;46:1226–30.CrossRefGoogle ScholarPubMed

Satlin, MJ, Calfee, DP, Chen, L, Fauntleroy, KA, Wilson, SJ, Jenkins, SG, et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma. 2013;54:799–806.CrossRefGoogle ScholarPubMed

Girmenia, C, Rossolini, GM, Piciocchi, A, Bertaina, A , Pisapia, G, Pastore, D, et al., for the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Infections by carbapenem-resistant Klebsiella pneumoniae in stem cell transplant recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50:282–8.CrossRefGoogle ScholarPubMed

Tomblyn, M, Chiller, T, Einsele, H, Gress, R, Sepkowitz, K, Storek, J, et al.; Center for International Blood and Marrow Research; National Marrow Donor Program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.CrossRefGoogle ScholarPubMed

Engelhard, D, Akova, M, Boeckh, MJ, Freifeld, A, Sepkowitz, K, Viscoli, C, et al.; Center for International Blood and Marrow Transplant Research; National Marrow Donor ProGram; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Disease Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Diseases Canada; Centers for Disease Control and Prevention. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44:467–70.CrossRefGoogle ScholarPubMed

Girmenia, C, Viscoli, C, Piciocchi, A, Cudillo, L, Botti, S, Errico, A, et al. Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica. 2015;100:e373–6.CrossRefGoogle ScholarPubMed

Meunier, F, Lukan, C. The First European Conference on Infections in Leukaemia – ECIL1: a current perspective. Eur J Cancer. 2008;44:2112–7.CrossRefGoogle ScholarPubMed

Kimura, S, Akahoshi, Y, Nakano, H, Ugai, T, Wada, H, Yamasaki, R, et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect. 2014;69:13–25.CrossRefGoogle ScholarPubMed

Guthrie, KA, Yong, M, Frieze, D, Corey, L, Fredricks, DN. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allo- hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:675–81.CrossRefGoogle Scholar

Eleutherakis-Papaiakovou, E, Kostis, E, Migkou, M, Christoulas, D, Terpos, E, Gavriatopoulou, M, et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing auto- stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol. 2010;85:863–7.CrossRefGoogle Scholar

Gafter-Gvili, A, Paul, M, Fraser, A, Leibovici, L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2007;59:5–22.CrossRefGoogle ScholarPubMed

Bow, EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24(6):545–53.CrossRefGoogle ScholarPubMed

Schmidt-Hieber, M, Labopin, M, Beelen, D, Volin, L, Ehninger, G, Finke, J, et al. CMV serostatus has still an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Blood. 2013;122(19):3359–64.CrossRefGoogle ScholarPubMed

Mariotti, J, Maura, F, Spina, F, Roncari, L, Dodero, A, Farina, L, et al. Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(6):885–90.CrossRefGoogle ScholarPubMed

Nichols, WG, Corey, L, Gooley, T, Davis, C, Boeckh, M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273–82.CrossRefGoogle ScholarPubMed

Pergam, SA, Xie, H, Sandhu, R, Pollack, M, Smith, J, Stevens-Ayers, T, et al. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2012;18(9):1391–400.CrossRefGoogle ScholarPubMed

Ljungman, P, Brand, R, Hoek, J, de la Camara, R, Cordonnier, C, Einsele, H, et al. Donor CMV status influences the outcome of allogeneic stem cell transplantation; a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014;59(4):473–81.CrossRefGoogle ScholarPubMed

Ljungman, P, Einsele, H, Frassoni, F, Niederwieser, D, Cordonnier, C. Donor CMV serological status influences the outcome of CMVseropositive recipients after unrelated donor stem cell transplantation: An EBMT Megafile analysis. Blood. 2003;102:4255–60.CrossRefGoogle Scholar

Boeckh, M, Nichols, WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103(6):2003–8.CrossRefGoogle ScholarPubMed

Preiksaitis, JK, Hayden, RT, Tong, Y, Pang, XL, Fryer, JF, Heath, AB, et al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016;63(5):583–9.CrossRefGoogle ScholarPubMed

Boeckh, M, Ljungman, P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.CrossRefGoogle ScholarPubMed

Lilleri, D, Gerna, G, Furione, M, Bernardo, ME, Giorgiani, G, Telli, S, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of pre-emptively treated children and young adults receiving haematopoietic stem cell transplantation as compared to qualitative pp65-antigenemia. Blood. 2007;110(7):2757–60.CrossRefGoogle Scholar

Milano, F, Pergam, SA, Xie, H, Leisenring, WM, Gutman, JA, Riffkin, I, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689–96.CrossRefGoogle ScholarPubMed

Reusser, P, Einsele, H, Lee, J, Volin, L, Rovira, M, Engelhard, D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159–64.CrossRefGoogle ScholarPubMed

Goodrich, JM, Mori, M, Gleaves, CA, Du Mond, C, Cays, M, Ebeling, DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325(23):1601–7.CrossRefGoogle ScholarPubMed

Volin, L, Barkholt, L, Nihtinen, A,Aschan, J, Uotinen, H, Hägglund, H, et al. An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplantation. 2008;42(Suppl.1):S47.Google Scholar

Ljungman, P, Perez-Bercoff, L, Jonsson, J, Avetisyan, G, Sparrelid, E, Aschan, J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78–83.Google ScholarPubMed

Milano, F, Campbell, AP, Guthrie, KA, Kuypers, J, Englund, JA, Corey, L, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115(10):2088–94.CrossRefGoogle Scholar

Winston, D, Young, J, Pullarkat, V, Papanicolaou, G, Vij, R, E V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111:5403–10.CrossRefGoogle ScholarPubMed

Marty, FM, Ljungman, P, Papanicolaou, GA, Winston, DJ, Chemaly, RF, Strasfeld, L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–92.CrossRefGoogle ScholarPubMed

Chemaly, RF, Ullmann, AJ, Stoelben, S, Richard, MP, Bornhauser, M, Groth, C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781–9.CrossRefGoogle ScholarPubMed

Marty, FM, Winston, DJ, Rowley, SD, Vance, E, Papanicolaou, GA, Mullane, KM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–36.CrossRefGoogle ScholarPubMed

Kharfan-Dabaja, M, Boeckh, M, Wilck, M, Langston, A, Chu, A, Wloch, M, et al. Phase 2 Trial of TransVax™, a Therapeutic DNA Vaccine for Control of Cytomegalovirus in Hematopoietic Cell Transplant Recipients 50th ICAAC; Boston, 2010: p. G1-1661a.

Chou, S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18(4):233–46.CrossRefGoogle ScholarPubMed

Chou, SW. Cytomegalovirus drug resistance and clinical implications. Transplant Infect Dis. 2001;3 (Suppl 2):20–4.CrossRefGoogle ScholarPubMed

Avery, RK, Marty, FM, Strasfeld, L, Lee, I, Arrieta, A, Chou, S, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infectious Dis. 2010;12(6):489–96.Google ScholarPubMed

Avery, RK, Mossad, SB, Poggio, E, Lard, M, Budev, M, Bolwell, B, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–26.CrossRefGoogle ScholarPubMed

Avery, RK, Bolwell, BJ, Yen-Lieberman, B, Lurain, N, Waldman, WJ, Longworth, DL, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 2004;34(12):1071–5.CrossRefGoogle Scholar

Kaptein, SJ, Efferth, T, Leis, M, Rechter, S, Auerochs, S, Kalmer, M, et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 2006;69(2):60–9.CrossRefGoogle ScholarPubMed

Lönnqvist, B, Ringdén, O, Ljungman, P, Wahren, B, Gahrton, G. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol. 1986;63(4):671–9.Google ScholarPubMed

Elmaagacli, AH, Steckel, NK, Koldehoff, M, Hegerfeldt, Y, Trenschel, R, Ditschkowski, M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402–12.CrossRefGoogle ScholarPubMed

Styczynski, J, Reusser, P, Einsele, H, de la Camara, R, Cordonnier, C, Ward, KN, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43(10):757-70.CrossRefGoogle ScholarPubMed

Styczynski, J, Gil, L, Tridello, G, Ljungman, P, Donnelly, JP, van der Velden, W, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57(6):794–802.CrossRefGoogle ScholarPubMed

Leong, HN, Tuke, PW, Tedder, RS, Khanom, AB, Eglin, RP, Atkinson, CE, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol. 2007;79(1):45–51.CrossRefGoogle ScholarPubMed

Hall, CB, Caserta, MT, Schnabel, K, Shelley, LM, Marino, AS, Carnahan, JA, et al. Chromosomal integration of human herpesvirus 6 is the major mode of congenital human herpesvirus 6 infection. Pediatrics. 2008;122(3):513-20.CrossRefGoogle ScholarPubMed

Schmidt-Hieber, M, Schwender, J, Heinz, WJ, Zabelina, T, Kuhl, JS, Mousset, S, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica. 2011;96(1):142–9.CrossRefGoogle ScholarPubMed

Seeley, WW, Marty, FM, Holmes, TM, Upchurch, K, Soiffer, RJ, Antin, JH, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007;69(2):156–65.CrossRefGoogle ScholarPubMed

Zerr, DM, Gooley, TA, Yeung, L, Huang, ML, Carpenter, P, Wade, JC, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;33(6):763–71.CrossRefGoogle ScholarPubMed

Zerr, DM, Fann, JR, Breiger, D, Boeckh, M, Adler, AL, Xie, H, et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood. 2011;117(19):5243–9.CrossRefGoogle ScholarPubMed

Scheurer, ME, Pritchett, JC, Amirian, ES, Zemke, NR, Lusso, P, Ljungman, P. HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis. Bone Marrow Transplant. 2013;48(4):574–80.CrossRefGoogle ScholarPubMed

Zerr, DM. Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation. J Clin Virol. 2006;37 (Suppl. 1):S52–6.CrossRefGoogle ScholarPubMed

Muta, T, Fukuda, T, Harada, M. Human herpesvirus-6 encephalitis in hematopoietic SCT recipients in Japan: a retrospective multicenter study. Bone Marrow Transplant. 2009;43(7):583–5CrossRefGoogle ScholarPubMed

Zerr, DM, Corey, L, Kim, HW, Huang, ML, Nguy, L, Boeckh, M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(7):932–40.CrossRefGoogle ScholarPubMed

Zerr, DM, Gupta, D, Huang, ML, Carter, R, Corey, L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(3):309–17.CrossRefGoogle ScholarPubMed

Tomblyn, M, Chiller, T, Einsele, H, Gress, R, Sepkowitz, K, Storek, J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant. 2009;44(8):453–5.CrossRefGoogle ScholarPubMed

Erard, V, Guthrie, KA, Varley, C, Heugel, J, Wald, A, Flowers, ME, et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV) disease following hematopoietic cell transplantation: no evidence of rebound VZV disease after drug discontinuation. Blood. 2007;110(8):3071–7.CrossRefGoogle Scholar

Feuchtinger, T, Lucke, J, Hamprecht, K, Richard, C, Handgretinger, R, Schumm, M, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128(4):503–9.CrossRefGoogle ScholarPubMed

Guerin-El Khourouj, V, Dalle, JH, Pedron, B, Yakouben, K, Bensoussan, D, Cordeiro, DJ, et al. Quantitative and qualitative CD4 T cell immune responses related to adenovirus DNAemia in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(4):476–85.CrossRefGoogle ScholarPubMed

Zandvliet, ML, van Liempt, E, Jedema, I, Kruithof, S, Kester, MG, Guchelaar, HJ, et al. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother. 2011;34(3):307–19.CrossRefGoogle ScholarPubMed

Lion, T, Kosulin, K, Landlinger, C, Rauch, M, Preuner, S, Jugovic, D, et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia. 2010;24(4):706–14.Google ScholarPubMed

Ohrmalm, L, Lindblom, A, Omar, H, Norbeck, O, Gustafson, I, Lewensohn-Fuchs, I, et al. Evaluation of a surveillance strategy for early detection of adenovirus by PCR of peripheral blood in hematopoietic SCT recipients: incidence and outcome. Bone Marrow Transplant. 2011;46(2):267–72.CrossRefGoogle ScholarPubMed

Matthes-Martin, S, Feuchtinger, T, Shaw, PJ, Engelhard, D, Hirsch, HH, Cordonnier, C, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transplant Infect Dis. 2012;14(6):555–63.CrossRefGoogle Scholar

Lion, T, Baumgartinger, R, Watzinger, F, Matthes-Martin, S, Suda, M, Preuner, S, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102(3):1114–20.CrossRefGoogle ScholarPubMed

Florescu, DF, Pergam, SA, Neely, MN, Qiu, F, Johnston, C, Way, S, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012;18(5):731–8.CrossRefGoogle ScholarPubMed

Grimley, M, Prasad, V, Kurtzberg, J, Chemaly, R, Brundage, T, Wilson, C, et al. Twice-Weekly Brincidofovir (CMX001) shows promising antiviral activity in immunocompromised transplant recipients with asymptomatic adenovirus viremia. Biol Blood Marrow Transplant. 2104;20(2 Suppl).Google Scholar

Campbell, AP, Guthrie, KA, Englund, JA, Farney, RM, Minerich, EL, Kuypers, J, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis. 2015;61(2):192–202.CrossRefGoogle ScholarPubMed

Lehners, N, Schnitzler, P, Geis, S, Puthenparambil, J, Benz, MA, Alber, B, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48(12):1548–53.CrossRefGoogle Scholar

Kim, YJ, Guthrie, KA, Waghmare, A, Walsh, EE, Falsey, AR, Kuypers, J, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195–204.CrossRefGoogle ScholarPubMed

Boeckh, M, Englund, J, Li, Y, Miller, C, Cross, A, Fernandez, H, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44(2):245–9.CrossRefGoogle ScholarPubMed

Shah, DP, Ghantoji, SS, Shah, JN, El Taoum, KK, Jiang, Y, Popat, U, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68(8):1872–80.CrossRefGoogle ScholarPubMed

Shah, JN, Chemaly, RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–63.CrossRefGoogle ScholarPubMed

Seo, S, Campbell, AP, Xie, H, Chien, JW, Leisenring, WM, Englund, JA, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant. 2013;19(4):589–96.CrossRefGoogle ScholarPubMed

Tramontana, AR, George, B, Hurt, AC, Doyle, JS, Langan, K, Reid, AB, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010;16(7):1068–75.CrossRefGoogle Scholar

Mohty, B, Thomas, Y, Vukicevic, M, Nagy, M, Levrat, E, Bernimoulin, M, et al. Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47(2):236–42.CrossRefGoogle ScholarPubMed

Lagler, H, Wenisch, JM, Tobudic, S, Gualdoni, GA, Rodler, S, Rasoul-Rockenschaub, S, et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine. 2011;29(40):6888–93.CrossRefGoogle ScholarPubMed

Ljungman, P, Ward, KN, Crooks, BN, Parker, A, Martino, R, Shaw, PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479–84.CrossRefGoogle ScholarPubMed

Ljungman, P, de la Camara, R, Perez-Bercoff, L, Abecasis, M, Nieto Campuzano, JB, Cannata-Ortiz, MJ, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011;96(8):1231–5.CrossRefGoogle ScholarPubMed

Casper, C, Englund, J, Boeckh, M. How I treat influenza in patients with hematologic malignancies. Blood. 2010;115(7):1331–42.CrossRefGoogle ScholarPubMed

Ljungman, P, Avetisyan, G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008;42(10):637–41.CrossRefGoogle ScholarPubMed

Rubin, LG, Levin, MJ, Ljungman, P, Davies, EG, Avery, R, Tomblyn, M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18.CrossRefGoogle ScholarPubMed

Machado, CM, Cardoso, MR, da Rocha, IF, Boas, LS, Dulley, FL, Pannuti, CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36(10):897–900.CrossRefGoogle ScholarPubMed

Engelhard, D, Mohty, B, de la Camara, R, Cordonnier, C, Ljungman, P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: Summary of ECIL-4 (2011). Transplant Infecti Dis. 2013;15(3):219–32.Google Scholar

Chemaly, RF, Hanmod, SS, Rathod, DB, Ghantoji, SS, Jiang, Y, Doshi, A, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012;119(12):2738–45; quiz 969.CrossRefGoogle ScholarPubMed

Srinivasan, A, Wang, C, Yang, J, Inaba, H, Shenep, JL, Leung, WH, et al. Parainfluenza virus infections in children with hematologic malignancies. Pediatr Infect Dis J. 2011;30(10):855–9.CrossRefGoogle ScholarPubMed

Ustun, C, Slaby, J, Shanley, RM, Vydra, J, Smith, AR, Wagner, JE, et al. Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. Biol Blood Marrow Transplant. 2012;8(10):1580–8.Google Scholar

Srinivasan, A, Wang, C, Yang, J, Shenep, JL, Leung, WH, Hayden, RT. Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1520–7.CrossRefGoogle ScholarPubMed

Seo, S, Xie, H, Campbell, AP, Kuypers, JM, Leisenring, WM, Englund, JA, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: viral detection in the lung predicts outcome. Clin Infect Dis. 2014;58(10):1357–68.CrossRefGoogle ScholarPubMed

Raza, K, Ismailjee, SB, Crespo, M, Studer, SM, Sanghavi, S, Paterson, DL, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26(8):862–4.CrossRefGoogle Scholar

Englund, JA, Boeckh, M, Kuypers, J, Nichols, WG, Hackman, RC, Morrow, RA, et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med. 2006;144(5):344–9.CrossRefGoogle ScholarPubMed

Renaud, C, Xie, H, Seo, S, Kuypers, J, Cent, A, Corey, L, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2013;19(8):1220–6.CrossRefGoogle ScholarPubMed

Seo, S, Martin, E, Xie, H, Kuypers, J, Campbell, A, Choi, S-M, et al. Human rhinovirus RNA detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality. Biol Blood Marrow Transplant. 2013;19(2 Suppl.):S167–S8.CrossRefGoogle Scholar

Lee, YJ, Zheng, J, Kolitsopoulos, Y, Chung, D, Amigues, I, Son, T, et al. Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T cell-depleted peripheral blood and cord blood stem cell transplantations. Biol Blood Marrow Transplant. 2014;20(8):1204-10.CrossRefGoogle Scholar

Leung, AY, Suen, CK, Lie, AK, Liang, RH, Yuen, KY, Kwong, YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 2001;98(6):1971–8.CrossRefGoogle ScholarPubMed

Gilis, L, Morisset, S, Billaud, G, Ducastelle-Lepretre, S, Labussiere-Wallet, H, Nicolini, FE, et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2014;49(5):664–70.CrossRefGoogle ScholarPubMed

Erard, V, Kim, HW, Corey, L, Limaye, A, Huang, ML, Myerson, D, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005;106(3):1130–2.CrossRefGoogle ScholarPubMed

Laskin, BL, Denburg, M, Furth, S, Diorio, D, Goebel, J, Davies, SM, et al. BK viremia precedes hemorrhagic cystitis in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1175–82.CrossRefGoogle ScholarPubMed

Cesaro, S, Facchin, C, Tridello, G, Messina, C, Calore, E, Biasolo, MA, et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(4):363–70.CrossRefGoogle ScholarPubMed

Cesaro, S, Hirsch, HH, Faraci, M, Owoc-Lempach, J, Beltrame, A, Tendas, A, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis. 2009;49(2):233–40.CrossRefGoogle ScholarPubMed

Kwon, HJ, Kang, JH, Lee, JW, Chung, NG, Kim, HK, Cho, B. Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience. Transplant Infect Dis. 2013;15(6):569–74.CrossRefGoogle ScholarPubMed

Ganguly, N, Clough, LA, Dubois, LK, McGuirk, JP, Abhyankar, S, Aljitawi, OS, et al. Low-dose cidofovir in the treatment of symptomatic BK virus infection in patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis of an algorithmic approach. Transplant Infect Dis. 2010;12(5):406–11.CrossRefGoogle ScholarPubMed

Chen, XC, Liu, T, Li, JJ, He, C, Meng, WT, Huang, R. Efficacy and safety of leflunomide for the treatment of BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Acta Haematol. 2013;130(1):52–6.CrossRefGoogle ScholarPubMed

Versluis, J, Pas, SD, Agteresch, HJ, de Man, RA, Maaskant, J, Schipper, ME, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(6):1079–86.CrossRefGoogle ScholarPubMed

Hammond, SP, Borchelt, AM, Ukomadu, C, Ho, VT, Baden, LR, Marty, FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(9):1049–59.CrossRefGoogle ScholarPubMed

Onozawa, M, Hashino, S, Izumiyama, K, Kahata, K, Chuma, M, Mori, A, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79(5):616–9.CrossRefGoogle ScholarPubMed

Arai, S, Lee, LA, Vogelsang, GB. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res. 2002;11(2):215–29.CrossRefGoogle ScholarPubMed

Lalazar, G, Rund, D, Shouval, D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136(5):699–712CrossRefGoogle ScholarPubMed

Mallet, V, van Bömmel, F, Doerig, C, Pischke, S, Hermine, O, Locasciulli, A, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16(5):606–17.CrossRefGoogle Scholar

Mahale, P, Kontoyiannis, DP, Chemaly, RF, Jiang, Y, Hwang, JP, Davila, M, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57(6):1177–85.CrossRefGoogle ScholarPubMed

Tomblyn, M, Chen, M, Kukreja, M, Aljurf, MD, Al Mohareb, F, Bolwell, BJ, et al. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transplant Infect Dis. 2012;14(5):468–78.CrossRefGoogle ScholarPubMed

Mahale, P, Okhuysen, PC, Torres, HA. Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol. 2014;12(6):1051–4 e1.CrossRefGoogle ScholarPubMed

Ljungman, P, Locasciulli, A, de Soria, VG, Bekassy, AN, Brinch, L, Espigado, I, et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant. 2012;47(9):1217–21.CrossRefGoogle ScholarPubMed

Peffault de Latour, R, Levy, V, Asselah, T, Marcellin, P, Scieux, C, Ades, L, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103(5):1618–24.CrossRefGoogle ScholarPubMed

Pasquini, MC, Wang, Z, Horowitz, MM, Gale, RP. Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clinical Transplants. 2010:87–105.

Girmenia, C, Raiola, AM, Piciocchi, A, Algarotti, A, Stanzani, M, Cudillo, L, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(6):872–80.Google Scholar

De Pauw, B, Walsh, TJ, Donnelly, JP, Stevens, DA, Edwards, JE, Calandra, T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(12):1813–21.CrossRefGoogle Scholar

Wingard, JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2002;35(7):891–5.CrossRefGoogle ScholarPubMed

Dodds Ashley, ES, Lewis, R, Lewis, JS, Martin, C, Andes, D. Pharmacology of systemic antifungal agents. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2006;43:S28–39.CrossRefGoogle Scholar

Walsh, TJ, Anaissie, EJ, Denning, DW, Herbrecht, R, Kontoyiannis, DP, Marr, KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(3):327–60.CrossRefGoogle ScholarPubMed

Maertens, J, Cornely, OA, Ullmann, AJ, Heinz, WJ, Krishna, G, Patino, H, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrobial Agents and Chemotherapy. 2014;58(7):3610–7.CrossRefGoogle ScholarPubMed

Girmenia, C, Barosi, G, Piciocchi, A, Arcese, W, Aversa, F, Bacigalupo, A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(8):1080–8.Google Scholar

Wingard, JR, Merz, WG, Rinaldi, MG, Johnson, TR, Karp, JE, Saral, R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. The New England Journal of Medicine. 1991;325(18):1274–7.CrossRefGoogle ScholarPubMed

Marr, KA, Seidel, K, Slavin, MA, Bowden, RA, Schoch, HG, Flowers, ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96(6):2055–61.Google ScholarPubMed

Winston, DJ, Maziarz, RT, Chandrasekar, PH, Lazarus, HM, Goldman, M, Blumer, JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Annals of Internal Medicine. 2003;138(9):705–13.CrossRefGoogle Scholar

Marr, KA, Crippa, F, Leisenring, W, Hoyle, M, Boeckh, M, Balajee, SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.Google ScholarPubMed

Vehreschild, JJ, Sieniawski, M, Reuter, S, Arenz, D, Reichert, D, Maertens, J, et al. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. International Journal of Antimicrobial Agents. 2009;34(5):446–50.CrossRefGoogle ScholarPubMed

Wingard, JR, Carter, SL, Walsh, TJ, Kurtzberg, J, Small, TN, Baden, LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–8.CrossRefGoogle ScholarPubMed

Marks, DI, Pagliuca, A, Kibbler, CC, Glasmacher, A, Heussel, CP, Kantecki, M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. British Journal of Haematology. 2011;155(3):318–27.CrossRefGoogle ScholarPubMed

Takagi, S, Araoka, H, Uchida, N, Uchida, Y, Kaji, D, Ota, H, et al. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning. International Journal of Hematology. 2014;99(5):652–8.Google ScholarPubMed

Cordonnier, C, Rovira, M, Maertens, J, Olavarria, E, Faucher, C, Bilger, K, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.CrossRefGoogle ScholarPubMed

Gergis, U, Markey, K, Greene, J, Kharfan-Dabaja, M, Field, T, Wetzstein, G, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GvHD. Bone Marrow Transplantation. 2010;45(4):662–7.CrossRefGoogle ScholarPubMed

Ullmann, AJ, Lipton, JH, Vesole, DH, Chandrasekar, P, Langston, A, Tarantolo, SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England Journal of Medicine. 2007;356(4):335–47.CrossRefGoogle ScholarPubMed

Sanchez-Ortega, I, Patino, B, Arnan, M, Peralta, T, Parody, R, Gudiol, C, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplantation. 2011;46(5):733–9.CrossRefGoogle ScholarPubMed

Winston, DJ, Bartoni, K, Territo, MC, Schiller, GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2011;17(4):507–15.CrossRefGoogle ScholarPubMed

Chaftari, AM, Hachem, RY, Ramos, E, Kassis, C, Campo, M, Jiang, Y, et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation. 2012;94(3):302–8.CrossRefGoogle ScholarPubMed

Hahn, J, Stifel, F, Reichle, A, Holler, E, Andreesen, R. Clinical experience with posaconazole prophylaxis: a retrospective analysis in a haematological unit. Mycoses. 2011;54 (Suppl 1):12–6.CrossRefGoogle Scholar

Chou, LS, Lewis, RE, Ippoliti, C, Champlin, RE, Kontoyiannis, DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12):1644–50.CrossRefGoogle ScholarPubMed

de Fabritiis, P, Spagnoli, A, Di Bartolomeo, P, Locasciulli, A, Cudillo, L, Milone, G, et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplantation. 2007;40(3):245–9.CrossRefGoogle ScholarPubMed

van Burik, JA, Ratanatharathorn, V, Stepan, DE, Miller, CB, Lipton, JH, Vesole, DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2004;39(10):1407–16.CrossRefGoogle ScholarPubMed

Huang, X, Chen, H, Han, M, Zou, P, Wu, D, Lai, Y, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(10):1509–16.CrossRefGoogle ScholarPubMed

Ziakas, PD, Kourbeti, IS, Mylonakis, E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clinical Therapeutics. 2014;36(2):292–306 e1.CrossRefGoogle ScholarPubMed

Jansen, J, Akard, LP, Wack, MF, Thompson, JM, Dugan, MJ, Leslie, JK, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses. 2006;49(5):397–404.CrossRefGoogle ScholarPubMed

Cordonnier, C, Mohty, M, Faucher, C, Pautas, C, Robin, M, Vey, N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. International Journal of Antimicrobial Agents. 2008;31(2):135–41.CrossRefGoogle ScholarPubMed

Penack, O, Schwartz, S, Martus, P, Reinwald, M, Schmidt-Hieber, M, Thiel, E, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2006;17(8):1306–12.CrossRefGoogle ScholarPubMed

Rijnders, BJ, Cornelissen, JJ, Slobbe, L, Becker, MJ, Doorduijn, JK, Hop, WC, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(9):1401–8.CrossRefGoogle ScholarPubMed

Walsh, TJ, Finberg, RW, Arndt, C, Hiemenz, J, Schwartz, C, Bodensteiner, D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. The New England Journal of Medicine. 1999;340(10):764–71.CrossRefGoogle ScholarPubMed

Wingard, JR, White, MH, Anaissie, E, Raffalli, J, Goodman, J, Arrieta, A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2000;31(5):1155–63.CrossRefGoogle ScholarPubMed

Walsh, TJ, Pappas, P, Winston, DJ, Lazarus, HM, Petersen, F, Raffalli, J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. The New England Journal of Medicine. 2002;346(4):225–34.CrossRefGoogle ScholarPubMed

Walsh, TJ, Teppler, H, Donowitz, GR, Maertens, JA, Baden, LR, Dmoszynska, A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. The New England Journal of Medicine. 2004;351(14):1391–402.CrossRefGoogle ScholarPubMed

Kubiak, DW, Bryar, JM, McDonnell, AM, Delgado-Flores, JO, Mui, E, Baden, LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clinical Therapeutics. 2010;32(4):637–48.CrossRefGoogle ScholarPubMed

Yamaguchi, M, Kurokawa, T, Ishiyama, K, Aoki, G, Ueda, M, Matano, S, et al. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Annals of Hematology. 2011;90(10):1209–17.CrossRefGoogle ScholarPubMed

Chen, SC, Slavin, MA, Sorrell, TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11–41.CrossRefGoogle ScholarPubMed

Anaissie, EJ, Vartivarian, SE, Abi-Said, D, Uzun, O, Pinczowski, H, Kontoyiannis, DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. The American Journal of Medicine. 1996;101(2):170–6.CrossRefGoogle ScholarPubMed

Mora-Duarte, J, Betts, R, Rotstein, C, Colombo, AL, Thompson-Moya, L, Smietana, J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. The New England Journal of Medicine. 2002;347(25):2020–9.CrossRefGoogle ScholarPubMed

Ullmann, AJ, Akova, M, Herbrecht, R, Viscoli, C, Arendrup, MC, Arikan-Akdagli, S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18 (Suppl 7):53–67.CrossRefGoogle Scholar

Pappas, PG, Rotstein, CM, Betts, RF, Nucci, M, Talwar, D, De Waele, JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2007;45(7):883–93.Google ScholarPubMed

Kuse, ER, Chetchotisakd, P, da Cunha, CA, Ruhnke, M, Barrios, C, Raghunadharao, D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–27.CrossRefGoogle ScholarPubMed

Ostrosky-Zeichner, L, Oude Lashof, AM, Kullberg, BJ, Rex, JH. Voriconazole salvage treatment of invasive candidiasis. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology. 2003;22(11):651–5.CrossRefGoogle ScholarPubMed

Kullberg, BJ, Sobel, JD, Ruhnke, M, Pappas, PG, Viscoli, C, Rex, JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–42.CrossRefGoogle ScholarPubMed

Herbrecht, R, Denning, DW, Patterson, TF, Bennett, JE, Greene, RE, Oestmann, JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. The New England Journal of Medicine. 2002;347(6):408–15.CrossRefGoogle ScholarPubMed

Bowden, R, Chandrasekar, P, White, MH, Li, X, Pietrelli, L, Gurwith, M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2002;35(4):359–66.CrossRefGoogle ScholarPubMed

Walsh, TJ, Raad, I, Patterson, TF, Chandrasekar, P, Donowitz, GR, Graybill, R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2007;44(1):2–12.CrossRefGoogle ScholarPubMed

Heinz, WJ, Grau, A, Ulrich, A, Helle-Beyersdorf, A, Zirkel, J, Schirmer, D, et al. Impact of benzodiazepines on posaconazole serum concentrations: a population-based pharmacokinetic study on drug interaction. Current Medical Research and Opinion. 2012;28(4):551–7.CrossRefGoogle ScholarPubMed

Jang, SH, Colangelo, PM, Gobburu, JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clinical Pharmacology and Therapeutics. 2010;88(1):115–9.CrossRefGoogle ScholarPubMed

Andes, D, Pascual, A, Marchetti, O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrobial Agents and Chemotherapy. 2009;53(1):24–34.CrossRefGoogle ScholarPubMed

Heinz, WJ, Einsele, H, Helle-Beyersdorf, A, Zirkel, J, Grau, A, Schirmer, D, et al. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease: An Official Journal of the Transplantation Society. 2013;15(5):449–56.Google ScholarPubMed

Lebeaux, D, Lanternier, F, Elie, C, Suarez, F, Buzyn, A, Viard, JP, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrobial Agents and Chemotherapy. 2009;53(12):5224–9.CrossRefGoogle ScholarPubMed

Cornely, OA, Helfgott, D, Langston, A, Heinz, W, Vehreschild, JJ, Vehreschild, MJ, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrobial Agents and Chemotherapy. 2012;56(5):2652–8.CrossRefGoogle ScholarPubMed

Denning, DW, Ribaud, P, Milpied, N, Caillot, D, Herbrecht, R, Thiel, E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2002;34(5):563–71.CrossRefGoogle ScholarPubMed

Pascual, A, Calandra, T, Bolay, S, Buclin, T, Bille, J, Marchetti, O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(2):201–11.CrossRefGoogle ScholarPubMed

Park, WB, Kim, NH, Kim, KH, Lee, SH, Nam, WS, Yoon, SH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2012;55(8):1080–7.CrossRefGoogle ScholarPubMed

Ueda, K, Nannya, Y, Kumano, K, Hangaishi, A, Takahashi, T, Imai, Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. International Journal of Hematology. 2009;89(5):592–9.CrossRefGoogle ScholarPubMed

Troke, PF, Hockey, HP, Hope, WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrobial Agents and Chemotherapy. 2011;55(10):4782–8.CrossRefGoogle ScholarPubMed

Maertens, J, Glasmacher, A, Herbrecht, R, Thiebaut, A, Cordonnier, C, Segal, BH, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888–97.CrossRefGoogle ScholarPubMed

Kontoyiannis, DP, Ratanatharathorn, V, Young, JA, Raymond, J, Laverdiere, M, Denning, DW, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infectious Disease: An Official Journal of the Transplantation Society. 2009;11(1):89–93.CrossRefGoogle ScholarPubMed

Meletiadis, J, Petraitis, V, Petraitiene, R, Lin, P, Stergiopoulou, T, Kelaher, AM, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in-vitro and in vivo correlation. The Journal of Infectious Diseases. 2006;194(7):1008–18.CrossRefGoogle ScholarPubMed

Marr, KA, Schlamm, H, Rottinghaus, ST,Jagannatha, S, Bow, EJ, Wingard, JR, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March–April, 2012.

Reed, C, Bryant, R, Ibrahim, AS, Edwards, J Jr., Filler, SG, Goldberg, R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;47(3):364–71.CrossRefGoogle ScholarPubMed

Cunha, C, Aversa, F, Lacerda, JF, Busca, A, Kurzai, O, Grube, M, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. The New England Journal of Medicine. 2014;370(5):421–32.CrossRefGoogle ScholarPubMed

Bochud, PY, Chien, JW, Marr, KA, Leisenring, WM, Upton, A, Janer, M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. The New England Journal of Medicine. 2008;359(17):1766–77.CrossRefGoogle ScholarPubMed